NEW YORK / May 23, 2024 / Business Wire / MultiPlan Corporation (NYSE: MPLN) (“MultiPlan” or the “Company”), a leading value-added provider of data analytics and technology-enabled end-to-end cost management, as well as payment and revenue integrity solutions to the U.S. healthcare industry, today announced the publication of its 2023 Environmental, Social, and Governance (ESG) Report.
The report follows the release of its inaugural ESG report last year, which detailed the structured assessment and reporting approach the Company undertakes to identify, prioritize, and monitor ESG risks and opportunities. The 2023 report showcases MultiPlan’s strategic momentum in advancing ESG priorities, its focus on managing, tracking, and disclosing on the Company’s progress, and its commitment to accountability and transparency.
“At MultiPlan, we are intensely focused on addressing the healthcare challenges of the people and communities we serve, and this includes operating as a sustainable company,” said Travis Dalton, President and CEO of MultiPlan. “The achievements outlined in the report demonstrate that we’re delivering on our responsibility to operate in a manner that creates long-term value for our business, our employees, our customers, our shareholders, and the communities in which we live and work.”
The report highlights MultiPlan’s progress and notable achievements related to its 2023 priority ESG issues of access to healthcare, data privacy and security, human capital management, diversity, inclusion, and belonging, ethics and transparency, corporate governance, and sustainable operations.
This includes:
The full report is available on MultiPlan’s website at the following link: https://www.multiplan.us/corporate-responsibility/.
About MultiPlan
MultiPlan is committed to bending the cost curve in healthcare by delivering transparency, fairness, and affordability to the US healthcare system. Our focus is on identifying medical savings, helping to lower out-of-pocket costs, and reducing or eliminating balance billing for healthcare consumers. Leveraging sophisticated technology, data analytics, and a team rich with industry experience, MultiPlan interprets clients’ needs and customizes innovative solutions that combine its payment and revenue integrity, network-based, data and decision science, and analytics-based services. MultiPlan delivers value to more than 700 healthcare payors, over 100,000 employers, 60 million consumers, and 1.4 million contracted providers. For more information, visit multiplan.com.
Forward Looking Statements
This MultiPlan ESG Report 2023 (this “Report”) includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of present or historical fact included in this Report, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “continue,” “project” or the negative of such terms and other similar expressions that predict or indicate future events or trends or that are not statements of present or historical matters. These statements are based on various assumptions, whether or not identified herein, and on the current expectations of the Company and are not predictions of actual outcomes. Actual events and circumstances are impossible to predict and are beyond the control of the Company.
The Company cautions you that these forward-looking statements are subject to numerous risk and uncertainties, most of which are difficult to predict and many of which are beyond the control of the Company. Additional risks and uncertainties that could affect the Company and its financial results are included in the Company’s most recent Annual Report on Form 10-K, as filed with the U.S. Securities and Exchange Commission (the “SEC”). Additional information will also be set forth in other filings that the Company makes with the SEC from time to time. All forward-looking statements in this Report are based on information available to the Company as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, changes in expectations, future events or otherwise.
Last Trade: | US$6.45 |
Daily Change: | 1.24 23.80 |
Daily Volume: | 138,164 |
Market Cap: | US$104.300M |
November 05, 2024 October 03, 2024 May 08, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB